相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders
Elon D. Wallert et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Correlations between blood lipid, serum cystatin C, and homocysteine levels in patients with Parkinson's disease
Jia Li et al.
PSYCHOGERIATRICS (2020)
Genetic variants of PARK genes in Korean patients with early-onset Parkinson's disease
Jinyoung Youn et al.
NEUROBIOLOGY OF AGING (2019)
THE TREATMENT OF ADVANCED PARKINSON'S DISEASE
Klivenyi Peter et al.
IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE (2018)
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1
Robert A. Hauser et al.
JOURNAL OF PARKINSONS DISEASE (2017)
Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study
S. Arora et al.
PARKINSONISM & RELATED DISORDERS (2015)
Safety and Efficacy of Rasagiline in Addition to Levodopa for the Treatment of Idiopathic Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials
Jiang-Ping Cai et al.
EUROPEAN NEUROLOGY (2015)
Molecular Effects of L-dopa Therapy in Parkinson's Disease
Jolanta Dorszewska et al.
CURRENT GENOMICS (2014)
Neuroimaging in Parkinson disease: from research setting to clinical practice
Marios Politis
NATURE REVIEWS NEUROLOGY (2014)
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naive Parkinson's disease
Marina Picillo et al.
JOURNAL OF NEUROLOGY (2013)
Enriched Early Life Experiences Reduce Adult Anxiety-Like Behavior in Rats: A Role for Insulin-Like Growth Factor 1
Sara Baldini et al.
JOURNAL OF NEUROSCIENCE (2013)
Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline
Peter Jenner et al.
MOVEMENT DISORDERS (2011)
Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease
Bradley J. Robottom
PATIENT PREFERENCE AND ADHERENCE (2011)
The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline
Orit Bar-Am et al.
JOURNAL OF NEUROCHEMISTRY (2010)
MOOD, ANXIETY, AND SERUM IGF-1 IN ELDERLY MEN GIVEN 24 WEEKS OF HIGH RESISTANCE EXERCISE
Ricardo C. Cassilhas et al.
PERCEPTUAL AND MOTOR SKILLS (2010)
Rescue of α-synuclein cytotoxicity by insulin-like growth factors
Shyan-Yuan Kao
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Homocysteine Is Not Associated with Global Motor or Cognitive Measures in Nondemented Older Parkinson's Disease Patients
Richard M. Camicioli et al.
MOVEMENT DISORDERS (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias
Stefano Zoccolella et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2006)
Neuropharmacolomcal, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline
MBH Youdim et al.
DRUGS OF TODAY (2005)
Effect of L-dopa on plasma homocysteine in PD patients relationship to B-vitamin status
JW Miller et al.
NEUROLOGY (2003)
Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic, neurons in models of Parkinson's disease
W Duan et al.
JOURNAL OF NEUROCHEMISTRY (2002)
分享论文
